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1040-8738 Copyright  2017 The Aa a,b,c,dNeringa Jurkute and Patrick Yu-Wai-ManPurpose of review
Leber hereditary optic neuropathy (LHON) is the most common primary mitochondrial DNA (mtDNA) genetic
disorder in the population. We address the clinical evolution of the disease, the secondary etiological factors
that could contribute to visual loss, and the challenging task of developing effective treatments.
Recent findings
LHON is characterized by a preclinical phase that reflects retinal ganglion cell (RGC) dysfunction before
rapid visual deterioration ensues. Children can present atypically with slowly progressive visual loss or an
insidious/subclinical onset that frequently results in considerable diagnostic delays. The LHON mtDNA
mutation is not sufficient on its own to precipitate RGC loss and the current body of evidence supports a
role for smoking and estrogen levels influencing disease conversion. Clinical trials are currently
investigating the efficacy of adeno-associated viral vectors-based gene therapy approaches for patients
carrying the m.11778G>A mutation. Mitochondrial replacement therapy is being developed as a
reproductive option to prevent the maternal transmission of pathogenic mtDNA mutations.
Summary
LHON is phenotypically more heterogeneous than previously considered and a complex interplay of
genetic, environmental and hormonal factors modulates the risk of a LHON carrier losing vision. Advances
in disease modelling, drug screening and genetic engineering offer promising avenues for therapeutic
breakthroughs in LHON.
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Inherited optic neuropathies are an important cause
of blindness in children and young adults [1]. The
advent of next-generation sequencing technology
has led to a rapidly expanding list of disease causing
genes and rather strikingly, all of them encode for
structural or functional proteins that contribute to
mitochondrial homeostasis. Leber hereditary optic
neuropathy (LHON) is the classical paradigm of a
mitochondrial optic neuropathy and historically, it
is the first disorder for which a pathogenic point
mutationwas ascribed to themitochondrial genome,
which is strictlymaternally inherited [2].Muchprog-
ress has been achieved since 1988whenWallace et al.
[3] identified the m.11778G>A mitochondrial DNA
(mtDNA) mutation in theMT-ND4 gene as the most
common cause of LHON (60%). The m.3460G>A
(MTND1) and m.14484T>C (MTND6) mutations
account for 15% of cases each, with the remainder
harbouring rarer mtDNA mutations [1].ht © 2017 Wolters Kluwe
uthor(s). Published by Wolters KluweThe prevalence of LHON has been well estab-
lished in Northern European populations with
figures ranging from one in 30000 to one in
50000 [4–6]. The incidence has proven morer Health, Inc. All rights reserved.
r Health, Inc. www.co-ophthalmology.com
KEY POINTS
 The onset of visual loss in LHON may be preceded by
a prodromal phase characterized by structural and
functional evidence of RGC dysfunction.
 Childhood LHON is a distinct subgroup that carries a
relatively more favourable prognosis compared with the
adult form of the disease.
 Environmental and hormonal factors are likely to
influence the overall risk of visual loss in LHON.
 Clinical trials are currently evaluating the therapeutic
benefit of gene therapy for patients carrying the
m.11778G>A mutation.
Ocular geneticsdifficult to establish in specific defined geographical
regions, but an estimate of one in 1000000 has
recently been reported in the Japanese population
[7
&
].
Visual recovery in LHON is influenced by the
underlyingmtDNAmutation, but overall, the visual
prognosis is poor and the majority of patients will
remain significantly visually impaired for the rest of
their lives [8]. Less than 20% of patients harbouring
the m.11778G>Amutation will recover 15 letters of
vision from the nadir compared with more favour-
able recovery rates of up to 60% for those with the
less deleterious m.14484T>C mutation [9,10
&&
].
Treatment options remain limited and this unsatis-
factory situation is further compounded by the
challenging nature of genetic counselling and our
incomplete understanding of the triggers for visual
loss in LHON [1,2].CLINICAL EVOLUTION
The acute stage of LHON is characterized by a rap-
idly evolving dense central or cecocentral scotoma.
In 25% of cases, both eyes are affected simulta-
neously [1,2]. In cases with unilateral disease onset,
the fellow eye is affected within 3–6 months.
Although the fundus can look entirely normal,
the optic disc is more commonly hyperaemic with
peripapillary telangiectasias and vascular tortuosity
of the central retinal vessels. There is pseudoedema
secondary to swelling of the retinal nerve fibre layer
(RNFL) and these morphological changes have been
documented more closely with the help of optical
coherence tomography (OCT) imaging. Disease
conversion in LHON is heralded by swelling of
the inferotemporal RNFL, which then propagates
circumferentially to involve the other sectors
around the optic disc [11,12]. The swelling gradually
subsides and the development of optic atrophy Copyright © 2017 Wolters Kluwer 
404 www.co-ophthalmology.comcoincides with progressive generalized RNFL
thinning over the subsequent 6–12 months. The
chronology and pathophysiological relevance of
these retinal ganglion cell (RGC) axonal changes
have been further clarified with high-resolution
spectral-domain OCT imaging. It is now apparent
that changes occurring at the macula, as measured
by the ganglion cell and inner plexiform layer
(GC-IPL) thickness, precede the wave of peripapil-
lary RNFL swelling in the acute stage of LHON [13
&&
].
In patients presenting with unilateral optic nerve
involvement, reduced GC-IPL thickness was noted
in the fellow (unaffected) eye 6 weeks before the
actual onset of visual loss and maximal thinning at
the macula had already occurred within 6 months.
Further work is needed to demonstrate whether
GC-IPL measurements could prove a more sensitive
biomarker for monitoring disease progression or
detecting a therapeutic response in clinical trials.
The preclinical stage has also been defined in
more detail based on the observations made in a
group of six LHON carriers from a large Brazilian
family carrying the m.11778A>G mutation who de-
veloped visual losswhilst being followedup as part of
a prospective natural history study [14
&&
]. An increase
in peripapillary RNFL thickness and a decrease in
mean deviation of up to 5dB on Humphrey visual
field perimetry were observed 4–6months before the
patient-reported subjective visual loss. A combina-
tion of OCT and visual field changes may therefore
help identify LHON carriers at high-risk for impend-
ing visual deterioration and perhaps, most likely to
benefit from early intervention when the means to
stop or slow RGC loss eventually becomes available.
The vascular changes in the acute stage of LHON
and the transient peripapillary telangiectasias seen
in asymptomatic mutation carriers are suggestive
clues pointing towards a possible vasculopathy
contributing to the complex pathophysiology of
this disorder. Thickening of the macular and
peripapillary choroidal layer has been reported in
the acute stage, followed by thinning in the chronic
stage [15]. The RNFL changes preceded the choroidal
changes, and it remains to be determined whether
the latter represents a compensatory response
secondary to a state of ‘pseudo-hypoxia’. OCT
angiography (OCT-A) is a promising development
in ocular imaging that is being used to delineate the
retinal vasculature in various pathological states,
including age-related macular degeneration and
diabetic retinopathy. Three case reports of OCT-A
in patients with acute LHON confirm the marked
vascular dilatation and tortuosity that is evident
clinically [16–18]. Importantly, there is no leakage
on fluorescein angiography, which differentiates
LHON from other inflammatory optic neuropathiesHealth, Inc. All rights reserved.
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intracranial pressure. In the chronic stage of LHON,
OCT-A shows extensive capillary drop out, in par-
ticular in the region of the papillomacular bundle.CHILDHOOD LEBER HEREDITARY OPTIC
NEUROPATHY
LHON is predominantly a disease of young adults
and the peak age of onset is in the second and third
decades of life. Less than 10%of patients are 12 years
old or younger at the time of diagnosis and previous
reports have described atypical patterns of visual
loss in this subgroup [19,20]. Childhood LHON
seems to carry a better visual prognosis compared
with the adult form of the disease. A recent meta-
analysis combined a British pediatric cohort of 27
patients with 69 additional cases that were identi-
fied from a systematic review of the literature [10
&&
].
The inclusion criteria were onset of visual loss at
12 years old or younger andmolecular confirmation
of one of the three primary mtDNA mutations
(m.3460G>A, m.11778G>A or m.14484T>C). The
phenotype in childhood LHON could be classified
into three distinct subtypes: first, classical acute,
which was the most common, being seen in about
two-thirds of all cases; second, slowly progressive, if
visual deterioration occurred over a period exceed-
ing 6 months and third, insidious or subclinical for
those individuals who were clinically asymptomatic
at the time that a diagnosis of optic atrophy or
subnormal vision was made, and in whom no fur-
ther decline in visual acuity occurred during subse-
quent follow-ups. This latter subgroup accounted
for 20% of cases and diagnostic delays of up to
15 years were encountered. A significant proportion
of patients (40%) achieved a final best-corrected
visual acuity (BCVA) at least6/12 Snellen in at least
one eye, but20% of patients did poorly with a final
BCVA less than 3/60 in their better seeing eye.
Although childhood onset is a positive prognostic
factor in LHON, a degree of caution is warranted as
part of counselling given that one in five patients
will remain within the visual acuity criteria for
legal blindness.
From a clinical perspective, LHON can have an
insidiousmanifestation in the paediatric population
and mtDNA genetic testing should be considered
when faced with a child with unexplained subnor-
mal vision and optic disc pallor to avoid potentially
prolonged diagnostic delays.INCOMPLETE PENETRANCE AND MALE
BIAS
LHON shows variable penetrance both between
families and within branches of the same family. Copyright © 2017 Wolters Kluwe
1040-8738 Copyright  2017 The Author(s). Published by Wolters KluweThe lifetime risk of a male carrier losing vision is
50% compared with 10% for a female LHON
carrier. The secondary factors that underlie this
incomplete penetrance and the strong male bias
for visual loss have been the subject of intense
investigation over the past 3 decades. Genetic
modelling initially pointed towards a nuclear
modifier gene on the X chromosome, but linkage
studies have been inconclusive with different
risk loci having been mapped and failure so far
to identify a causative gene that segregates with
affected disease status in LHON [21–23]. The
current body of evidence points towards LHON
being a complex disease with multifactorial
genetic and environmental triggers interacting
with the LHON mtDNA mutation [24]. Uncover-
ing the nature of these modulatory factors has
been difficult for several reasons, in particular,
the relatively rarity of LHON for conducting ade-
quately powered, large-scale genomic studies and
the difficulty in collecting accurate environmental
exposure data.ENVIRONMENTAL TRIGGERS
A number of retrospective epidemiological studies
have provided convincing evidence that heavy
smoking, and to a lesser extent excessive alcohol
consumption, is a major risk factor for visual loss in
LHON [25–27]. It is biologically plausible that these
environmental triggers play a more prominent role
for mutation carriers who experience visual loss in
later life, presumably because they have a lower a
priori nuclear genetic predisposition [28,29]. There
are potential confounding factors inherent in the
retrospective recall and analysis of environmental
exposure, but the deleterious impact of smoking
on mitochondrial function has been confirmed
in vitro with the use of primary LHON fibroblasts
established from affected and unaffected mutation
carriers [30
&
]. Cells that were cultured under the
influence of cigarette smoke demonstrated a signi-
ficant reduction in ATP synthesis, which is to be
expected given that LHONmtDNAmutations affect
critical subunits of the mitochondrial respiratory
chain complexes. More prominent oxidative
damage were also found in fibroblasts from affected
mutation carriers implying a reduced capacity
to mitigate the effect of impaired mitochondrial
electron flux and the consequent toxic elevation
in reactive oxygen species (ROS) levels. LHON
mutation carriers should therefore be strongly
advised not to smoke and to moderate their drink-
ing habits as these are the only modifiable risk
factors over which they have a personal degree
of control.r Health, Inc. All rights reserved.
r Health, Inc. www.co-ophthalmology.com 405
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A longstanding hypothesis is whether the striking
sex bias in LHON could arise because of hormonal
differences, especially the higher levels of circulat-
ing estrogens in women. This would imply a second
peak of female LHON carriers converting in the
perimenopausal or menopausal period, but there
is no robust data yet to suggest that this is the case.
RGCs express high levels of the estrogen beta recep-
tor and estrogen derivatives are known to exert a
neuroprotective effect under conditions of height-
ened cellular stress [31,32]. The work of Giordano
et al. have provided convincing experimental proof
that estrogen derivatives were effective in partially
rescuing the downstream consequences of LHON
mtDNA mutations on mitochondrial function in a
well characterized LHON cybrid model [33,34
&
].
When treated with a specific combination of
phytoestrogens, which are natural estrogen-like
compounds, LHON cybrids showed improved mito-
chondrial respiratory chain function, lower ROS
levels and a reduced sensitivity to undergo apopto-
sis. These promising in-vitro results will need to be
pursued further and if confirmed, the next step
would be to screen for estrogen derivatives that
are mitochondrial protective, whilst not having
any of the adverse side effects of sustained estrogen
use, especially feminising effects and an increased
risk of breast and gyaecological cancers if the treat-
ment is to be given prophylactically to male and
female LHON carriers, respectively.FROM BENCH TO BEDSIDE
LHON is a frustrating condition for patients, their
families and the physicians looking after them. The
stark reality is that there is currently no treatment
that will reverse the catastrophic loss of RGCs
that occurs rapidly in the first few weeks of disease
onset [35]. The development of treatment para-
digms for LHON and other mitochondrial optic
neuropathies has been severely hampered by the
inability to study disease mechanisms directly in
RGCs and the lack of animal models that faithfully
replicate the optic neuropathy and clinical mani-
festations.
Idebenone is a synthetic, short-chain analogue
of ubiquinone, which improves the shuttling of
electrons from complexes I and II directly to com-
plex III. Idebenone is partially effective when given
in the acute stage of LHON, but only a subgroup of
patients experience a clinically significant visual
benefit [36–38]. There is clearly the need to develop
more targeted treatments that will block one or
more of the key pathways that link mitochondrial
dysfunction with optic nerve neurodegeneration in Copyright © 2017 Wolters Kluwer 
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necessary and the ultimate objective would be to
prevent RGC loss in the first place for those LHON
carriers deemed to be at high risk of disease conver-
sion based on preexisting susceptibility factors and/
or the presence of ophthalmological features presag-
ing imminent deterioration in visual acuity.THERAPEUTIC DRUG SCREENING
Mitochondria exist as a highly interconnected net-
work that extends throughout the cell and mtDNA
copy number is a surrogate marker of a cell’s bio-
energetic demand. Significantly, mtDNA copy num-
ber was found to be significantly higher in
unaffected LHON carriers compared with affected
LHON carriers in a range of tissues that were tested,
including peripheral blood cells, skeletal muscle
biopsies and cells isolated by laser capturing post-
mortem specimens of retina and optic nerves
[39,40]. Improved mitochondrial biogenesis could
therefore be a key compensatory mechanism that
protects some LHON carriers from losing vision.
This hypothesis is further borne out by the emerging
story with regard to tobacco toxins and estrogens,
which decrease and increase mtDNA copy number,
respectively, potentially accounting for their influ-
ence on disease penetrance [30
&
,34
&
].
A recent paper highlighted that an imbalance
between nicotinamide adenine dinucleotide (NADþ)
and the reduced form of NADþ (NADH) could be
theunifying link throughwhich impairedmitochon-
drial oxidative phosphorylation (OXPHOS) results in
RGC loss in both aged mice and a glaucoma mouse
model [41
&&
,42]. Boosting the level of NADþ by long-
term dietary supplementation with the NADþ pre-
cursor nicotinamide (vitamin B3) or gene therapy
prevented RGC dysfunction and neuronal loss, pro-
viding an attractive therapeutic paradigm for glauco-
ma and, by extrapolation, mitochondrial optic
neuropathies.
High-throughput drug screening is another
possible way forward to identify molecules with a
positive effect on mitochondrial biogenesis and
OXPHOS, and these could then be further tested
in RGCs, which are the susceptible neuronal popu-
lation in LHON. Induced pluripotent stem cells can
now be routinely produced by reprogramming
peripheral blood cells or fibroblasts obtained from
a punch skin biopsy [43]. In parallel, differentiation
protocols are being refined by a number of research
groups worldwide to allow the efficient generation
of various retinal cells, including RGCs, providing
an ideal ‘disease in a dish’ model for testing promis-
ing drug molecules in a more physiological setting
[44–46].Health, Inc. All rights reserved.
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Despite the complexity in unravelling the secondary
modifiers that precipitate visual loss, LHON is still
amenable to classical gene therapy with replace-
ment of themissing protein product. Mitochondrial
gene therapy is a challenging task because of the
physical barrier imposed by having two mitochon-
drial membranes and the need for sustained gene
expression following delivery of the gene construct
into the mitochondrial matrix compartment [47].
To circumvent these technical difficulties, one inge-
nious option is allotopic gene expression whereby
the gene construct is inserted into the nuclear ge-
nome, and the resulting protein has amitochondrial
targeting sequence, which then allows its import
into the mitochondrial compartment [48]. Geneti-
cally modified adeno-associated viral vectors
(AAV2) have been developed to deliver the MT-
ND4 gene construct as a therapeutic strategy to
compensate for the m.11778G>A mutation
[49,50]. Preclinical data have provided consistent
results supporting therapeutic rescue in vitro and a
reduction in the amount of RGCs lost in the relevant
murinemodels tested, which was associated with an
improvement in visual function. Some investigators
have expressed legitimate concerns regarding the
efficiency with which the imported ND4 subunit
will integrate into Complex I and whether this will
result in a sufficiently stable complex to promote the
efficient flow of electrons along the mitochondrial
respiratory chain [47,51]. Preliminary data from
early-phase clinical trials support the previously
established safety of AAV2-based gene therapy
vectors and an encouraging visual trend for the eyes
that have been treated with a single intravitreal in-
jection [52–54]. The efficacy of this therapeutic
paradigm for patients with LHON still needs to be
established and three clinical trials (NCT02161380,
NCT02652767 and NCT02652780, https://clinical
trials.gov/ct2/home, accessed on 1 June 2017) are
currently recruiting patients in Europe and North
America to evaluate the optimal dose and the effects
of treatment at different stages of the disease process.MITOCHONDRIAL REPLACEMENT
THERAPY
LHON is a disease of young adults and reproductive
choice is a topic of discussion that is frequently
raised by patients and other maternally related fam-
ily members during genetic counselling. Some fe-
male carriers, most of whom will be unaffected, are
keen to have their own biological children, but they
are understandably anxious about the future impli-
cations for their children who will be inheriting
their mtDNA mutation. Copyright © 2017 Wolters Kluwe
1040-8738 Copyright  2017 The Author(s). Published by Wolters KluweMitochondrial replacement techniques have
been developed to prevent the maternal transmis-
sion of mtDNA mutations, some of which cause
early-onset, severe and invariably fatal encephalo-
myopathies [47,55,56]. The methods being pro-
posed are based on modification of established
IVF techniques. They involve the transfer of paren-
tal nuclear material into a mitochondrial donor
zygote carrying only wild-type mtDNA and the ex-
perimental data obtained so far has been encourag-
ing with minimal carry over of mutant mtDNA
[57
&&
,58
&&
]. In a primate model, embryonic develop-
ment proceeded normally following implantation
of the embryos, resulting in the births of healthy
offspring [57
&&
,58
&&
]. This reproductive approach
remains controversial as it entails germline modifi-
cation with a child inheriting genetic material from
a third person, albeit a limited number of 37 mito-
chondrial genes compared with the estimated
20000 genes that constitute the nuclear genome.
The concern also relates to the possibility that the
adverse effects from this new genetic admixture
might not become apparent until later in life
[47,55,56]. The scientific and ethical debate as to
whether mitochondrial donation should be offered
to prospective mothers carrying pathogenic mtDNA
mutations has accelerated further when the media
released the somewhat unexpected news about the
first live birth arising from mitochondrial replace-
ment in September 2016 [59
&&
,60]. The child’s
mother is heteroplasmic for the m.8993T>G
mtDNA mutation in MT-ATP6, which in addition
to the syndrome of neuropathy, ataxia and retinitis
pigmentosa can also cause Leigh syndrome when
present at high mutant levels. Although clinically
asymptomatic, she suffered from multiple miscar-
riages and two of her children died at the age of
8months and 6 years old from Leigh syndrome with
the m.8993T>Gmutation detected at levels exceed-
ing 95%. The newly born baby boy was reported to
be healthy at 7 months age and relatively low levels
of the mutation (2.4–9.2%) were detected in the
tissues that were analysed. The child’s neurodeve-
lopmental progress will be carefully reviewed and
fertility testing will be considered when he reaches
the age of 18 years. Following an extensive public
consultation exercise and a stringent scientific
peer review process, the Human Fertilisation and
Embryology Authority in the United Kingdom has
granted a licence in March 2017 for the first clinic
to be set up in Newcastle upon Tyne, United
Kingdom, to provide mitochondrial donation as a
reproductive option for eligible female carriers
harbouring disease-causing mtDNA mutations
(http://www.hfea.gov.uk/10635.html, accessed on
1 June 2017).r Health, Inc. All rights reserved.
r Health, Inc. www.co-ophthalmology.com 407
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The past 5 years have seen a major shift in LHON
research to clinical translation and there is renewed
hope that the translational gap can be bridged by
bringing together scientific communities with dif-
ferent skill sets and fostering greater collaborations
with industry, patient-led organizations and nation-
al regulatory agencies, which until recently only had
a limited understanding of the unique challenges of
research into rare diseases. Experimental therapies
by their very nature impose a degree of calculated
risks on the participants, and the onus is on the
physicians and researchers involved to clearly com-
municate the nature of the intervention being stud-
ied, the benefits that are being contemplated, and
crucially, the grey areas that will only be answered
with long-term follow-up. LHON causes devastating
visual loss and the urgent need to develop and
validate new treatment strategies should not cloud
our judgement that patient safety should always
remain the abiding central factor. There will inevi-
tably be set-backs along the way, but the major
breakthroughs being achieved in the fields of ocular
phenotyping, diseasemodelling, drug screening and
genomic manipulation all point towards a building
momentum that will help drive LHON research
forward.
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